The trailing P/E of 5.29 compares favorably on screen with loss-making peers Recursion (P/E -3.02), Schrödinger (-21.89) and Absci (-14.14), making CGEN look like the only reasonably priced asset in the group. That contrast is misleading: Innoviva at a 6.40 P/E sustains a 63.8% net margin, whereas Compugen's normalized operating result is a quarterly loss, so stripping the one-time gain likely renders forward P/E and EV/EBITDA undefined rather than cheap. Investors should treat the current multiple set as an artifact of recognition timing, not a discount to intrinsic franchise value.

The 84.4% net margin recorded in Q4 2025 reflects revenue recognition on a discrete transaction rather than operating leverage, since research and development averaged roughly $6.3M per quarter through 2025-2026 and remains the dominant cost center. By 2026Q2 the net margin had reverted to -2.7%, which suggests true earning power is still loss-making at the current cost structure. Any credible earnings-quality assessment should therefore normalize to the pre-event baseline, where gross margin negativity implies the company's commercial revenue does not yet cover direct costs.

Return on equity followed an identical arc, moving from 77.6% to -7.6%, and ROA from 44.7% to -4.9%, which tells us the swing was driven almost entirely by the income spike rather than any change in the capital base. Stretching the window, ROIC between 2022 and 2023 sat between -8.5% and -35.5%, so the company has no multi-year record of compounding returns and the windfall period should be excluded from any return trajectory analysis.

The compression in DPO from 394 days in 2025Q1 to 79 days in 2026Q2 may indicate suppliers were paid down once post-event cash arrived, tightening the free working capital float at exactly the moment cash reserves fell to $10.3M. Cash conversion cycle is unavailable throughout, as DIO is blank, which is consistent with an asset-light R&D model carrying no inventory rather than a data failure. Consequently, the usual efficiency readouts offer little forward signal and should not be extrapolated.

With a debt-to-equity ratio of 0.03 and no interest coverage disclosed, debt servicing does not compound the pressure, so the binding constraint is absolute cash rather than solvency. Deferred revenue has grown to $31.8M from zero in 2023, which may replenish liquidity if the underlying milestones are achieved, but the timing of those inflows is not visible in the data and warrants further investigation. Against an observed post-windfall burn that consumed roughly $80M of equity value in two quarters, the runway appears materially shorter than the headline ratio suggests.